Albireo Pharma, Inc. (ALBO)
| Market Cap | 446.49M |
| Revenue (ttm) | 10.77M |
| Net Income (ttm) | -47.87M |
| Shares Out | 19.28M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,760 |
| Open | 23.62 |
| Previous Close | 23.38 |
| Day's Range | 22.86 - 23.82 |
| 52-Week Range | 21.51 - 43.41 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 76.00 (+228.2%) |
| Earnings Date | Nov 4, 2021 |
About ALBO
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also d...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 76.00, which is an increase of 228.15% from the latest price.
News
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
– New chief business officer to oversee Company's corporate and business development strategy – – New chief business officer to oversee Company's corporate and business development strategy –
Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Albireo Reports Q3 Financial Results and Business Update
– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 '21 revenue of $1.1 million –
Albireo Pharma (ALBO) to Report Q3 Results: Wall Street Expects Earnings Growth
Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albireo to Report Third Quarter 2021 Financial Results on November 4
— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan
– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –
Albireo Recognizes PFIC Awareness Day 2021
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network ...
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
– Listed on the German national price list and all pharmacy software programs –
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stoc...
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –
Albireo Pharma Sells Bylvay-Associated PRV For $105M
Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrah...
Albireo to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President a...
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –
ALBIREO PHARMA (ALBO) Reports Q2 Loss, Misses Revenue Estimates
ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of 1.04% and -6.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Albireo Reports Q2 Financial Results and Business Update
– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC –
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...
Albireo to Report Second Quarter 2021 Financial Results on August 5
— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial...
MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients Wit...
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Famili...
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-syste...
Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive F...
– First approval in the world of Bylvay for the treatment of PFIC –